Research programme: cardiovascular therapeutics - Sumocor
Alternative Names: N-106Latest Information Update: 28 Feb 2022
At a glance
- Originator SUMOCOR
- Class Cardiovascular therapies; Proteins; Small molecules
- Mechanism of Action SUMO-1 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cardiovascular disorders
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for preclinical development in Cardiovascular-disorders in USA
- 29 Mar 2018 Novoheart files for patent protection for MyHeart™ platform for Cardiovascular disorders
- 14 Feb 2018 Novoheart and Sumocor agree to co-develop cardiovascular therapeutics for Cardiovascular disorders